Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced financial results for the third quarter and nine months ended September 30, 2008, and highlighted several recent product developments and corporate milestones.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Recent product and corporate highlights:

o On October 8, 2008, the company announced that it will initiate a

corporate restructuring that will extend the company's financial

resources to pursue near-term corporate development opportunities,

including completion of a merger and acquisition (M&A) transaction,

the sale of specific programs, and/or completion of other

alternative financial arrangements.

o The company announced positive clinical results from its Phase 1

trial of HspE7, a therapeutic treatment for patients with cervical

intraepithelial neoplasia, or CIN, a precursor to cervical cancer.

During the third quarter, immunological data from the fourth and

final cohort of the Phase 1 trial demonstrated absolute levels of

HPV16 E7-specific T-cells in patients were similar to levels

observed in the third cohort. Patients in the fourth cohort were

administered 500 mcg of HspE7 and 2,000 mcg of Poly-ICLC. These data

support doses of 500 mcg of HspE7 and 1,000-2,000 mcg of Poly ICLC

as appropriate for advancing into Phase 2 studies.

o During the quarter, the company won a challenge to its European

patent covering the company's lead product candidate, HspE7, and

other human papillomavirus (HPV) therapeutics.

o Nventa presented positive data from preclinical studies using its

proprietary Toll-like Receptor 3 agonis
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm Clinic ... about Appearance Medicine . Although Dr. Hart regularly teaches ... to lecture in China, and quite a different experience it ... 12 and 7 million people respectively. Interest in cosmetic facial ... in time. As Dr. Hart passed through the Fuzhou airport ...
(Date:5/16/2013)... Needham, Mass. (PRWEB) May 16, 2013 ... Bioprocessing Summit from August 19-23, 2013 at the Renaissance ... comprising the Summit provide a close-up look at the ... risk and ensuring bottom-line quality. Leaders in the ... innovative ways to produce biopharmaceuticals with greater specificity and ...
(Date:5/16/2013)... Ore. , May 16, 2013  HealthSparq, ... many of the nation,s largest regional health plans, ... America,s Health Insurance Plans (AHIP) Institute 2013 conference ... highlight survey results showing how health insurance companies ... for the consumer and marketplace demands for increased ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Energy crop company,Ceres, Inc. announced today that ... hybrids with Range Fuels, Inc. as part,of a ... Range Fuels,commercial-scale cellulosic ethanol plant, now under construction ... While wood residues will be the primary ...
... IRVINE, Calif., Sept. 9 SectorWatch.biz announces ... the news and,driving markets today. MarketStats offers ... opportunity for investors to respond with,articles, blogs ... by visiting: http://www.SectorWatch.biz ,-- a division ...
... to be Tested on Type 2 Diabetic Volunteers, ... ORMP.OB) ( http://www.oramed.com ), a developer,of oral delivery ... with,ETI Karle Clinical Pvt. Ltd. ( http://www.etiklinical.com ), ... conduct Phase 2B clinical,trials on its oral insulin ...
Cached Biology Technology:Ceres Trials Energy Crops at Georgia Biofuel Facility 2Ceres Trials Energy Crops at Georgia Biofuel Facility 3SectorWatch.biz Issues MarketStats on Agri-Biotech Equities YGYB, GRO, SEED, MON, ADM, and BG 2Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 2Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801 3
(Date:5/17/2013)... The State University of New Jersey, and City University ... called Visikol TM that effectively clears organisms to ... place of chloral hydrate, which is one of the ... tightly regulated by the Drug Enforcement Administration (DEA) due ... or clearing agents, are vital for viewing organisms under ...
(Date:5/17/2013)... of proteins in the brain responsible for protecting nerve ... could increase cell survival. , The discovery, made by ... in the EMBO journal with additional comment ... for stroke and other brain diseases. , The research ... a protein, known as SUMO, responsible for controlling the ...
(Date:5/17/2013)... The iCargo project (Intelligent Cargo in Efficient and Sustainable ... thanks to an improvement in the efficiency of intermodal ... assist decision making. It comprises 29 European organisations with ... management. It has a budget totalling 17,000,000 and a ... is working to specify and develop the semantic components ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3SUMO wrestling cells reveal new protective mechanism target for stroke 2New logistics services that will cut energy consumption and CO2 emissions 2
... and videos! , With their long stalks and feathery ... like their garden-variety namesakes. Perhaps because of that resemblance, scientists ... moving around like their stalkless relatives, the feather stars. ... a depth of 430 meters (1410 feet) near Grand Bahama ...
... study from the forthcoming Quarterly Review of Biology, biologists ... types of laughter ?laughter which is stimulus-driven and laughter ... occurs during everyday social interaction in response to banal ... Matthew Gervais and David Sloan Wilson. "The unstated issue ...
... Earth's landscape , The ice ages made massive changes to ... in the oceans? , Research by marine scientists reveals that ... of animals were wiped out by ice sheets scouring the ... that these ecosystems somehow dodged extinction by recolonising from nearby ...
Cached Biology News:U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 2U. of Colorado researcher identifies tracks of swimming dinosaur in Wyoming 3Seafloor creatures destroyed by ice action during ice ages 2
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
... with Purpose -- The Varian ... the highest level of flexibility ... an affordable, easy-to-use system. The ... workstation guarantees success with today's ...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
... 0.5-10 Kb RNA Ladder is suitable for sizing single-stranded ... glyoxal or formaldehyde agarose gels. The ladder consists of ... 3 4 6 8 and 10 kb) to simplify ... than the other bands allowing easy orientation and identification ...
Biology Products: